Evaluation of CA-125 and soluble CD-23 in patients with pelvic endometriosis: a case-control study  by Luna Ramos, Ivana Maria de et al.
ARTIGO ORIGINAL
SUMMARY
Objective: To evaluate serum concentrations of CA-125 and soluble CD-23 and to correlate 
them with clinical symptoms, localization and stage of pelvic endometriosis and histological 
classification of the disease. Methods: Blood samples were collected from 44 women with 
endometriosis and 58 without endometriosis, during the first three days (1st sample) and dur-
ing the 7th, 8th and 9th day (2nd sample) of the menstrual cycle. Measurements of CA-125 
and soluble CD-23 were performed by ELISA. Mann-Whitney U test was used for age, pain 
evaluations (visual analog scale) and biomarkers concentrations. Results: Serum levels of CA-
125 were higher in endometriosis patients when compared to the control group during both 
periods of the menstrual cycle evaluated in the study. This marker was also elevated in women 
with chronic pelvic pain, deep dyspareunia (2nd sample), dysmenorrhea (both samples) and 
painful defecation during the menstrual flow (2nd sample). CA-125 concentration was higher 
in advanced stages of the disease in both samples and also in women with ovarian endo-
metrioma. Concerning CD-23, no statistically significant differences were observed between 
groups. Conclusion: The concentrations of CA-125 were higher in patients with endometrio-
sis than in patients without the disease. No significantly differences were observed for soluble 
CD-23 levels between groups.
Keywords: Endometriosis; biological markers; symptoms; CA-125 antigen.
RESUMO
Avaliação do CA-125 e CD-23 solúvel em pacientes com endometriose 
pélvica: estudo de caso-controle 
Objetivo: Avaliar as concentrações séricas de CA-125 e CD-23 solúvel e correlacioná-los com 
sintomas clínicos, localização e estádio da endometriose pélvica e classificação histológica da 
doença. Métodos: Amostras de sangue foram coletadas de 44 mulheres com endometriose e 
58 sem endometriose durante os primeiros três dias (1ª amostra) e durante o sétimo, o oitavo 
e o nono dia (2ª amostra) do ciclo menstrual. As dosagens de CA-125 e CD-23 solúvel foram 
realizadas por ELISA. O teste U de Mann-Whitney foi usado para idade, avaliação de dor 
(escala analógica visual) e para a concentração dos biomarcadores. Resultados: Os níveis sé-
ricos de CA-125 foram mais altos nas pacientes com endometriose do que no grupo-controle 
quando avaliados em ambos os períodos do ciclo menstrual, assim como apresentaram-se 
elevados nessas mulheres quando referiam dor pélvica crônica, dispareunia de profundidade 
(coleta na 2ª amostra), dismenorreia (ambas as amostras) e dor ao evacuar durante o fluxo 
menstrual (coleta na 2ª amostra). A concentração de CA-125 foi mais alta no estádio avan-
çado em ambas as amostras, assim como em mulheres com endometriomas ovarianos. Em 
relação ao CD-23 solúvel, nenhuma diferença estatisticamente significativa foi observada en-
tre os grupos. Conclusão: As concentrações de CA-125 foram mais altas em pacientes com 
endometriose do que em pacientes sem a doença. Nenhuma diferença estatisticamente signi-
ficativa foi observada para CD-23 solúvel entre os grupos.
Unitermos: Endometriose; marcadores biológicos; sintomas; antígeno Ca-125.
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INTRODUCTION
The most accurate procedure for diagnosis of endo-
metriosis is laparoscopy, an invasive surgical method. 
The definitive diagnosis is based on the visualization of the 
characteristic lesions and on histological confirmation. 
The identification of less invasive and more accessible 
markers of the disease is suitable. Several studies have 
reported that CA-125, a glycoprotein of epithelial origin 
found in normal cells, has high serum concentrations in 
patients with endometriosis, mainly when evaluated dur-
ing the menstrual flow1-3.
Another biomarker of interest to this study was sol-
uble CD-23, a protein that is expressed on the surface of 
cell membrane, commonly identified as the low affinity 
IgE receptor on B cells, eosinophils, monocytes, dendritic 
cells, epithelial Langerhans cells and platelets4.
Based on the evidence of increased concentrations of 
soluble CD-23 in peritoneal fluid of women with endo-
metriosis, it was suggested that the disease would acti-
vate B cells, which would promote the release of higher 
concentrations of soluble CD-235,6. This hypothesis was 
strengthened by the identification that women treated 
with danazol had a greater reduction in the concentration 
of CD-23 when compared to patients treated with leupro-
lide acetate. If danazol could suppress humoral and cell-
mediated immune responses and could alter macrophage 
function, by a significant increase of soluble leukocyte an-
tigen class I and class II (HLA-I and HLA-II), due to the 
release of these antigens from intracellular stores, it could 
also promote the reduction of inflammatory process in 
endometriosis. It would activate anti-inflammatory cyto-
kines, similar to what occurs in normal pregnancy, creat-
ing an inhospitable environment for the establishment of 
ectopic endometrium. Based on these arguments, it was 
suggested that changes in the levels of HLA by danazol 
may reflect the immune competence and the function 
of macrophages in endometriosis7,8. Thus, the hypoth-
esis stated by Odukoya et al.9 has reinforced that soluble 
CD-23 may be involved in the development and mainte-
nance of endometriosis and may serve as a possible bio-
logical marker.
The presence of soluble CD-23 in patients with endo-
metriosis could occur because the endometrial cells that, 
by reflux, reach the peritoneal cavity are presented by 
macrophages and other antigen presenting cells to CD4+ 
T cells that become activated by cytokines, as IL-4 and IL-
10. Recently, our group reported that these cytokines are 
increased in patients with endometriosis and promote the 
release of CD-23 by B cells and monocytes10. Thus, CD-23 
concentration could also be elevated as a consequence of 
increased concentration of cytokines.
The aim of this study was to determine serum concen-
trations of CA-125 and soluble CD-23 in patients with and 
without endometriosis, in two phases of the menstrual 
cycle: 1st, 2nd or 3th day and 8th, 9th or 10th day. We also 
compared the concentrations of CA-125 and CD-23 with 
clinical symptoms, stage and site of the lesions and histo-
logical classification of the disease.
METHODS 
PATIENTS 
This study was approved by the Ethics in Research Com-
mittee of Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo. From June 2007 to Oc-
tober 2010, the following inclusion criteria were applied 
to 1,920 consecutive patients complaining of infertility, 
pelvic pain or desire for family planning by tubal ligation: 
age between 18 and 45 years, absence of hormone therapy 
within three months prior to consultation, absence of au-
toimmune diseases confirmed by history and laboratory 
tests, when necessary; evidence of ovarian function and 
laparoscopy examination for the investigation of infertil-
ity or pelvic pain refractory to clinical therapy, based on 
complaints and on gynecological examination or imag-
ing findings, consistent with endometriosis. 
One hundred and four patients met inclusion criteria 
and were invited to participate in the study, after having 
been informed about the research objectives. Patients 
underwent medical history, to investigate the presence 
of six symptoms most commonly associated with endo-
metriosis: dysmenorrheal, chronic pelvic pain, deep dys-
pareunia, infertility, bowel and urinary cyclic symptoms. 
The intensity of chronic pelvic pain and dyspareunia was 
evaluated using a visual analogue scale of 10 points. Pel-
vic examination was the next step, searching for retro-
uterine nodules, thickening of the uterosacral ligament 
or pelvic masses. Patients with endometriosis clinical 
suspicion was submitted to pelvic and transvaginal ultra-
sound and, when necessary, to pelvic MRI. Laparoscopy 
was indicated in the presence of pain even after clinical 
treatment or if the image exams showed ovarian endome-
trioma and/or deep infiltrative lesions affecting retrocer-
vical region, vagina, bowel, bladder or ureter.
Up to three months before laparoscopy, after eight 
hours fasting, all patients had a venipuncture to col-
lect 5 mL of blood sample that was stored in a dry tube. 
The first sampling occurred between the 1st, 2nd or 3th day 
of the menstrual cycle and the second at the 8th, 9th or 
10th day. The samples were sent to a freezer, maintained at 
–20° C, at the laboratory and the analysis was performed 
after the collection of all samples. 
After laparoscopy, patients were divided into two 
groups: the first (case group) consisted of 45 patients with 
a diagnosis of endometriosis confirmed by pathological 
examination. The second (control group) consisted of 59 
women without endometriosis. One patient in the case 
group and another in the control group left the research. 
Thus, the case group was composed of 44 patients and the 
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control group, of 58 patients. In the case group, the dis-
ease was classified according to American Society for Re-
productive Medicine11 stages and location of the disease. 
In the histological analysis of excised tissues, we followed 
the classification pattern proposed by Abrão et al.12.
LABORATORY ANALYSIS
The determination of serum CA-125 levels was per-
formed using a sandwich technique of a commercial ELI-
SA kit (Elecsys®, Roche — NY, USA) and the dosage of 
serum soluble CD-23 was also performed with a ELISA 
kit (Bender MedSystems, Vienna, Austria) according to 
manufacturers instructions. The analyte range of CA-125 
and soluble CD-23 is 25-35 IU/mL and 10-91 U/mL, re-
spectively.
STATISTICAL ANALYSIS 
Statistical analysis was performed to compare Ca-125 
and CD-23 concentrations with case and control groups 
regarding the presence and intensity of clinical com-
plaints related to endometriosis, site of disease, staging 
according to the ASRM and histopathological analysis. 
We compared means using a Mann-Whitney U test, with 
5% significance level. 
RESULTS
We found that CA-125 average concentrations were sig-
nificantly higher in cases when compared to controls, 
both at first and second periods of collection, and soluble 
CD-23 average concentrations of cases were lower when 
compared to the control group, but it did not reach sta-
tistical significance (Table 1). It was identified that the 
average concentration of CA-125 in the second collection 
allowed differentiating cases from controls with chronic 
pelvic pain (VAS >  6), as well as the presence of deep 
dyspareunia. The differentiation of patients with intense 
chronic pelvic pain was also possible by CA-125/soluble 
CD-23 ratios, in the second collection (Table 1).
As for dysmenorrhea, we found that CA-125 average 
concentrations, in both collections, differentiated cases 
and controls when the complaint of infertility was ab-
sent and when the intensity of dysmenorrhea was high 
(VAS > 6). This differentiation was also possible by bio-
markers ratio, in the second collection (Table 1). Re-
garding the presence of intestinal symptoms, cases and 
controls were differentiated by mean concentrations of 
CA-125, soluble CD-23 and CA-125/soluble CD-23 ra-
tios, also in the second collection (Table 2).
Concerning the lesions sites, it was observed that 
patients with endometriosis in all sites had higher 
CA-125 mean concentrations when compared to the con-
trol group, in both blood collections. The same was not 
observed in terms of average concentrations of soluble 
CD-23 (Table 3).
In advanced endometriosis (stage III or IV), the mean 
concentrations of CA-125, in both collections, were higher 
than in initial endometriosis (stage I or II) and in absence 
of endometriosis (Table 3). 
DISCUSSION 
In the present study, serum levels of CA-125 were higher 
in endometriosis patients when compared to the control 
group during both periods of the menstrual cycle evalu-
ated in the study. CA-125 concentration was higher in ad-
vanced stages of the disease in both samples and also in 
women with ovarian endometrioma. Concerning CD-23, 
no statistically significant differences were observed be-
tween groups.
CA-125 has been extensively studied and is considered 
a useful tool for clinical diagnosis of endometriosis2-4,13,14-16. 
High CD-23 concentrations have been observed in peri-
toneal fluid of women with endometriosis, suggesting the 
activation of B cells and a possible imbalance of humoral 
immune system in endometriosis6-8,17.
The decision to evaluate these markers in two stages of 
the menstrual cycle was taken from studies that showed 
fluctuations in their concentrations, especially CA-125 
during the menstrual cycle. Kafali et al.2 identified in wom- 
en without endometriosis an increase of CA-125 concen-
tration of 22% during menstruation, compared to other 
days of the cycle. Abrão et al.3 demonstrated that during 
the first three days of the menstrual cycle, CA-125 con-
centrations were greater than the eighth and tenth day of 
the cycle.
Our study is the first one that evaluates both mark-
ers (CA-125 and CD-23) in patients with endometriosis. 
Although there is no direct relationship between markers 
CA-125 and CD-23, both participate in the pathophysiol-
ogy of endometriosis (proliferation and epithelial cellular 
inflammatory response/immune, respectively), justifying 
the assessment of these two markers in the same cohort 
of patients with and without endometriosis. Moreover, as 
panel markers evaluation has been previously published 
and still no satisfactory results were found, we thought 
that the association of these two markers could improve 
the auxiliary value of laboratory tests in predicting endo-
metriosis using a non-invasive diagnosis method.
In the present study, the average concentrations of CA-
125, higher in the case group than in the control group, 
reinforced the assertion that this marker may be useful as 
an auxiliary diagnosis and management of endometrio-
sis. Analyzing our results, we found that the average con-
centrations of CA-125 in the first collection (on the first, 
second or third day of the menstrual cycle) were always 
higher than in the second (eighth, ninth or tenth day of 
the cycle), both in cases and controls. Abrão et al.3,18 re-
ported the same results evaluated in serum samples ob-
tained during the menstrual cycle: on day 1, 2 or 3 of the 
EVALUATION OF CA-125 AND SOLUBLE CD-23 IN PATIENTS WITH PELVIC ENDOMETRIOSIS: A CASE-CONTROL STUDY
29Rev Assoc Med Bras 2012; 58(1):26-32
Table 1 – CA-125, sCD-23 and CA-125/sCD-23 levels in cases and control samples according to chronic pelvic pain, deep 
dyspareunia and dysmenorrhea
CA-125 sCD-23 CA-125/sCD-23
Samples Samples Samples
1st 2nd 1st 2nd 1st 2nd
Cases (n = 44) 51.98 ± 7.88 42.23 ± 5.66 42.85 ± 3.93 52.98 ± 10.58 1.64 ± 0.29 1.32 ± 0.22
Controls (n = 58) 29.19 ± 5.65 21.20 ± 2.78 54.47 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
p-value 0.018 0.001 0.132 0.697 0.048 0.017
Chronic pelvic pain            
Absent            
Case (n = 15) 47.01 ± 15.18 39.15 ± 1.8 47.43 ± 6.31 79.01 ± 28.48 0.98 ± 0.27 0.8 ± 0.22
Control (n = 28) 21.28 ± 3.0 19.09 ± 2.89 58.36 ± 11.33 54.37 ± 9.28 0.93 ± 0.25 0.76 ± 0.17
p-value 0.117 0.092 0.504 0.315 0.902 0.897
1 to 5            
Case (n = 11) 78.83 ± 19.40 54.58 ± 12.01 39.27 ± 10.21 34.75 ± 7.74 2.70 ± 0.8 2.04 ± 0.6
Control (n = 18) 38.82 ± 16.29 27.21 ± 7.62 59.28 ± 13.85 68.42 ± 19.61 1.07 ± 0.4 0.87 ± 0.28
p-value 0.132 0.053 0.314 0.125 0.053 0.058
6 to 10            
Case (n = 18) 39.72 ± 7.4 37.26 ± 7.69 41.23 ± 5.39 42.43 ± 7.86 1.54 ± 0.41 1.32 ± 0.33
Control (n = 12) 33.21 ± 10.28 17.10 ± 2.03 47.88 ± 10.67 51.26 ± 15.25 1.0 ± 0.28 0.53 ± 0.11
p-value 0.602 0.02 0.547 0.578 0.339 0.033
Deep dyspareunia            
Absent            
Case (n = 19) 54.74 ± 14.4 37.78 ± 8.2 48.22 ± 8.36 52.87 ± 8.82 1.27 ± 0.31 0.84 ± 0.14
Control (n = 30) 32.95 ± 8.56 21.81 ± 3.86 52.7 ± 8.99 54.86 ± 11.06 1.1 ± 0.25 0.78 ± 0.16
p-value 0.186 0.051 0.768 0.914 0.698 0.845
Present            
Case (n = 25) 41.8 ± 6.92 37.84 ± 5.83 37.17 ± 4.23 51.45 ± 17.65 1.86 ± 0.45 1.59 ± 0.36
Control (n = 18) 24.24 ± 4.47 21.28 ± 4.19 56.04 ± 10.75 59.59 ± 12.02 0.9 ± 0.26 0.75 ± 0.21
p-value 0.058 0.039 0.116 0.728 0.078 0.05
Dysmenorrhea            
Absent            
Case (n = 2) 135.55 ± 102.45 103.35 ± 69.85 41.2 ± 12.6 37.95 ± 9.05 2.79 ± 1.63 2.4 ± 1.26
Control (n = 18) 18.22 ± 2.52 16.25 ± 2.37 59.06 ± 14.09 52.26 ± 12.15 0.65 ± 0.16 0.38 ± 0.18
p-value 0.457 0.430 0.686 0.706 0.414 0.013
1 to 5            
Case (n = 5) 66.24 ± 39.15 35.34 ± 10.26 37.56 ± 6.29 39.62 ± 5.65 1.74 ± 0.91 0.89 ± 0.21
Control (n = 11) 59.76 ± 28.0 34.03 ± 13.02 53.7 ± 19.85 69.97 ± 22.23 1.51 ± 0.64 1.15 ± 0.48
p-value 0.897 0.950 0.538 0.212 0.842 0.726
6 to 10            
Case (n = 37) 45.54 ± 6.09 39.86 ± 5.54 43.66 ± 4.58 55.6 ± 12.53 1.57 ± 0.32 1.32 ± 0.26
Control (n = 29) 24.4 ± 2.3 19.41 ± 1.89 54.79 ± 9.13 57.19 ± 11.88 1.0 ± 0.25 0.63 ± 0.11
p-value 0.002 0.001 0.250 0.928 0.184 0.017
sCD-23, soluble CD-23; case, patients with endometriosis; control, patients without endometriosis; 1st, second or third day of the menstrual 
cycle; 2nd, eight, ninth or tenth day of the menstrual cycle.
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cycle and on day 8, 9 or 10 of the cycle and compared to 
stage of the disease. The advanced stage of the disease was 
also associated with high levels of CA-125. It could also 
be noted that the average concentrations of CA-125 dif-
ferentiate patients with stromal or well differentiated glan-
dular pattern from those without the disease only in the 
second sampling. This detailed analysis between concen-
trations of CA-125 and histological classification (stromal 
and glandular pattern) of pelvic endometriosis was not yet 
reported in the literature, which hindered the discussion 
of our findings. Also, in terms of stages of endometriosis, 
Mihalyi et al.19 reported differences in the concentration 
of CA-125 between cases and controls. It is noteworthy 
that these authors made this statement not only by using 
the CA-125 as complementary diagnostic biomarker, but 
they associated it with CA-19-9, IL-6, IL-8, high sensitivity 
C-reactive protein and tumor necrosis factor alpha, which 
seems to justify a greater sensitivity and specificity.
The average concentration of CA-125 allowed us to 
differentiate cases and controls in the second collec-
tion, in the presence of chronic pelvic pain and dys-
menorrheal, deep dyspareunia and intestinal symptoms 
as well as intense dysmenorrhea, in the first collection. 
These findings agreed with Barbosa et al.14, who reported 
Table 2 – CA-125, sCD-23 and CA-125/sCD-23 levels in cases and control samples according to infertility, urinary and 
intestinal symptoms
CA-125 sCD-23 CA-125/sCD-23
Samples Samples Samples
1st 2nd 1st 2nd 1st 2nd
Infertility            
Absent            
Case (n = 18) 45.67 ± 8.07 44.04 ± 7.51 43.8 ± 5.4 42.05 ± 5.75 1.4 ± 0.3 1.42 ± 0.3
Control (n = 30) 21.89 ± 2.11 17.93 ± 1.83 53.94 ± 10.09 54.73 ± 12.92 0.76 ± 0.15 0.64 ± .12
p-value 0.01 0.003 0.464 0.444 0.035 0.028
Present            
Case (n = 16) 46.1 ± 13.59 30.63 ± 7.64 40.38 ± 7.87 65.68 ± 27.41 1.55 ± 0.47 0.8 ± 0.17
Control (n = 17) 29.91 ± 8.15 21.1 ± 4.39 58.18 ± 12.97 66.94 ± 15.92 1.14 ± 0.39 0.74 ± 0.21
p-value 0.308 0.281 0.257 0.968 0.503 0.813
Never tried            
Case (n = 10) 72.78 ± 23.03 57.53 ± 16.61 45.1 ± 7.65 52.34 ± 13.54 20.21 ± 0.89 1.99 ± 0.74
Control (n = 11) 47.97 ± 26.65 30.26 ± 12.14 60.75 ± 18.37 53.54 ± 12.1 1.4 ± 0.64 1.04 ± 0.44
p-value 0.494 0.195 0.457 0.948 0.463 0.275
Cyclical intestinal symptoms            
Absent            
Case (n = 26) 56.71 ± 11.6 43.55 ± 7.66 47.56 ± 4.63 64.69 ± 17.03 1.39 ± 0.27 1.0 ± 0.16
Control (n = 35) 31.32 ± 8.65 23.87 ± 4.38 52.72 ± 9.33 47.50 ± 7.4 1.06 ± 0.24 0.93 ± 0.18
p-value 0.078 0.031 0.657 0.315 0.365 0.790
Present            
Case (n = 18) 45.16 ± 9.67 40.33 ± 8.57 36.04 ± 6.74 36.07 ± 6.88 2.0 ± 0.59 1.79 ± 0.48
Control (n = 23) 25.94 ± 5.65 17.14 ± 2.09 62.19 ± 11.52 74.19 ± 16.7 0.89 ± 0.29 0.46 ± 0.1
p-value 0.079 0.017 0.058 0.044 0.098 0.014
Cyclical urinary symptoms            
Absent            
Case (n = 44) 51.98 ± 7.88 42.23 ± 5.66 42.85 ± 3.93 52.98 ± 10.57 1.64 ± 0.29 1.32 ± 0.22
Control (n = 54) 30.19 ± 6.04 21.82 ± 2.97 54.12 ± 7.2 56.32 ± 8.34 1.02 ± 0.19 0.77 ± 0.13
p-value 0.031 0.002 0.173 0.802 0.065 0.034
sCD-23, soluble CD-23; case, patients with endometriosis; control, patients without endometriosis; 1st, second or third day of the menstrual 
cycle; 2nd, eight, ninth or tenth day of the menstrual cycle.
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that the presence of endometriotic lesions in symptom-
atic patients remained correlated with the expression of 
CA-125. Some authors suggest a correlation between lev-
els of CA-125 and the proliferative activity of epithelial 
cells in the lesions of endometriosis, because the disease 
is an inflammatory process associated with a change in 
immune cell functions20,21. For some patients, the gyne-
cologic examination may be normal as well as the symp-
toms may be absent, especially for those with superficial 
peritoneal disease22. By comparing patients without en-
dometriosis to those with endometriosis according to 
location of the ectopic implants, we concluded that the 
concentrations of CA-125 differed from the cases with 
ovarian endometriosis, which may be due to increased 
blood supply in that location, which would determine 
higher expression of the marker by epitheliocytes23.
Concerning soluble CD-23, there are few studies in 
the literature which correlate this marker with endo-
metriosis5-7,9. The comparison of average concentrations 
between cases and controls failed to distinguish the 
presence or absence of endometriosis. By analyzing the 
relationship between the symptoms of endometriosis and 
the concentrations of soluble CD-23, our results demon-
strated that, in the second collection, there was a signifi-
cant difference between cases and controls with intestinal 
symptoms.
The most relevant findings of our study were the con-
firmation of CA-125 as an auxiliary biological marker 
able to differentiate cases and controls. High CA-125 
levels were associated with clinical symptoms such as 
chronic pelvic pain, dysmenorrhea, deep dyspareunia, 
bowel symptoms, and contribute to the diagnosis of ovar-
CA-125 sCD-23 CA-125/sCD-23
Samples Samples Samples
1st 2nd 1st 2nd 1st 2nd
Localization            
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Ovarian (n = 9) 92.37 ± 26.88 64.86 ± 15.40 44.71 ± 5.3 46.31 ± 4.49 2.28 ± 0.63 1.5 ± 0.35
p-value 0.048 0.022 0.528 0.208 0.079 0.029
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Peritoneal (n = 20) 41.04 ± 8.52 32.09 ± 6.67 38.02 ± 6.77 59.04 ± 22.5 1.82 ± 0.53 1.48 ± 0.44
p-value 0.278 0.144 0.158 0.960 0.148 0.121
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Deep (n = 15) 42.34 ± 9.62 42.18 ± 9.77 48.18 ± 6.5 48.91 ± 8.83 1.02 ± 0.25 1.02 ± 0.23
p-value 0.283 0.055 0.572 0.582 0.939 0.306
p inter-localizations 0.03 0.092 0.518 0.874 0.256 0.628
ASRM classiﬁcation            
I-II (n = 19) 41.79 ± 8.94 32.59 ± 7.01 37.86 ± 7.13 60.16 ± 23.69 1.89 ± 0.55 1.52 ± .46
III-IV (n = 25) 59.73 ± 12.02 49.56 ± 8.24 46.64 ± 4.28 47.53 ± 5.47 1.46 ± 0.29 1.18 ± 0.19
p-value 0.265 0.14 0.274 0.56 0.468 0.446
Histological classiﬁcation            
Control (n = 58) 29.19 ± 5.65 21.20 ± 2.78 56.48 ± 7.21 58.08 ± 8.09 0.99 ± 0.18 0.75 ± 0.12
Stromal (n = 11) 55.22 ± 17.94 38.6 ± 7.09 46.72 ± 3.06 47.65 ± 3.36 1.21 ± 0.42 0.82 ± 0.14
Glandular well differentiated
(n = 27)
48.66 ± 7.84 41.22 ± 7.11 42.42 ± 6.18 43.73 ± 6.89 1.87 ± 0.42 1.48 ± 0.33
Glandular undifferentiated  
(n = 2)
35.9 ± 6.8 33.3 ± 10.0 39.05 ± 12.35 32.65 ± 10.85 1.08 ± 0.52 1.26 ± 0.72
Mixed glandular (n = 4) 73.58 ± 54.84 63.52 ± 37.98 37.02 ± 7.7 140.25 ± 109.12 1.57 ± 0.95 1.69 ± 0.84
p-value 0.807 0.692 0.926 0.07 0.78 0.627
sCD-23, soluble CD-23; control, patients without endometriosis; 1st, second or third day of the menstrual cycle; 2nd, eight, ninth or tenth day of the menstrual cycle.
Table 3 – CA-125, sCD-23 and CA-125/sCD-23 levels according to the site of the disease, ASRM staging and histolological 
classiﬁcation
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ian endometriosis. Moreover, it was possible to identify 
an association between the presence of intestinal symp-
toms and the average concentration of soluble CD-23 in 
the second collection.
Furthermore, one limitation of this study is the small 
number of samples in some of the groups evaluated. It 
may have contributed to the lack of association between 
the markers and some parameters analyzed in this study. 
A greater number of samples could contribute to a better 
accuracy of the parameters evaluated.
CONCLUSION
Our results do not invalidate the warning that for some 
patients physical examination may be normal as well as 
symptoms may be absent, especially for those with super-
ficial peritoneal disease. The ratio of the markers allows 
us to differentiate cases and controls with severe chronic 
pelvic pain (ranging from 6 to 10 – VAS), presence of 
severe dysmenorrhea, infertility absence, presence and 
absence of intestinal symptoms of urinary symptoms.
Thus, this study confirms that the noninvasive diag-
nosis of endometriosis remains a challenge despite the 
increase in diagnostic possibilities, represented by mea-
surement of CA-125 and soluble CD-23.
REFERENCES
1. McLeod BS, Retzloff MG. Epidemiology of endometriosis: an assessment of 
risk factors. Clin Obstet Gynecol. 2010;53:389-96.
2. Kafali H, Artuc H, Demir N. Use of CA-125 fluctuation during the menstrual 
cycle as a tool in the clinical diagnosis of endometriosis; a preliminary re-
port. Eur J Obstet Gynecol. 2004;116:85-8.
3. Abrão MS, Podgaec S, Martorelli Filho B, Ramos LO, Pinotti JA, Oliveira 
RM. The use of biochemical markers in the diagnosis of pelvic endometrio-
sis. Human Reprod. 1997;12:2523-7.
4. Hassa H, Tanir MH, Teckin B, Kirilmaz SD, Matlu FS. Cytokine and immune 
cell levels in peritoneal fluid and peripheral blood of women with early-and 
late-staged endometriosis. Arch Gynecol Obstet. 2009;279:891-5.
5. Odukoya OA, Bansal A, Wilson P, Lim K, Weetman AP, Cooke ID. Serum 
soluble CD 23 in patients with endometriosis and the effect of treatment with 
danazol and leuprolide acetate depot injection. Hum Reprod. 1995;10:942-6.
6. Odukoya OA, Bansal A, Cooke ID. Serum endometrial IgG antibodies and 
soluble CD 23 concentrations in patients with endometriosis. Acta Obstet 
Gynecol Scand. 1996;75:927-31.
7. Matalliotakis IM, Neonaki MA, Koumantaki Y, Goumenou AG, Kyriakou 
DS, Koumantakis EE. A randomized comparison of danazol and leuprolide 
acetate suppression of serum-soluble CD-23 levels in endometriosis. Obstet 
Gynecol. 2000;95:810-13.
8. Matalliotakis IM, Athanassakis I, Goumenou AG, Neonaki MA, Koumantakis 
EE, Vassiliadis S, et al. The possible anti-inflammatory role of circulating human 
leukocyte antigen levels in women with danazol and leuprorelin acetate depot. 
Mediators Inflamm. 2001;10:75-80.
9. Odukoya OA, Bansal A, Wilson P, Lim K, Weetman AP, Cooke ID. Soluble 
CD-23 protein in the peritoneal fluid of patient with endometriosis. Hum 
Reprod. 1996;11:2018-21.
10. Podgaec S, Abrão MS, Dias Jr JA, Rizzo LV, Oliveira RM, Baracat EC. En-
dometriosis: an inflammatory disease with a Th2 immune response compo-
nent. Hum Reprod. 2007;22:1373-9.
11. ASRM. American Society for Reproductive Medicine. Revised American So-
ciety for Reproductive Medicine classification of endometriosis. Fertil Steril. 
1997;67:817-821.
12. Abrão MS, Nerme RM, Carvalho FM, Aldrighi JM, Pinotti JA. Histological 
classification of endometriosis as a predictor of response to treatment. Int J 
Gynecol Obstet. 2003;82:31-41.
13. Ghaemmaghami F, Zarchi MK, Hamedi B. High levels of CA125 (over 1,000 
IU/ml) in patients with gynecologic disease and no malignant conditions: 
three cases and literature review. Arch Gynecol Obstet. 2007;276:559-61.
14. Barbosa CP, Souza AMB, Bianco B, Christofolini D, Bach FAM, Lima GR. 
Frequency of endometriotic lesions in peritoneum samples from asymp-
tomatic fertile women and correlation with CA125 values. São Paulo Med J. 
2009;127:342-5.
15. Bellelis P, Dias Jr JA, Podgaec S, Gonzales M, Baracat EC, Abrão MS. Epi-
demiological and clinical aspects of pelvic endometriosis-a case series. Rev 
Assoc Med Bras. 2010;56:467-71.
16. Petta CA, Matos AM, Bahamondes L, Faúndes D. Current practice in the 
management of symptoms of endometriosis: a survey of Brazilian gynecolo-
gists. Rev Assoc Med Bras. 2007;53:525-9.
17. Podgaec S, Dias Junior JA, Chapron C, Oliveira RM, Baracat EC, Abrão MS. 
Th1 and Th2 ummune responses related to pelvic endometriosis. Rev Assoc 
Med Bras. 2010;56:92-8.
18. Abrão MS, Podgaec S, Pinotti JA, Oliveira RM. Tumor markers in endome-
triosis. Int J Gynaecol Obstet. 1999;66:19-22.
19. Mihalyi A, Gevaert O, Kyama CM, Simsa P, Pochet N, De Smet F, et al. Non-
invasive diagnosis of endometriosis based on a combined analysis of six 
plasma biomarkers. Hum Reprod. 2010;25:654-64.
20. Agic A, Xu H, Finas D, Banz C, Diedrich K, Hornung D. Is endometriosis 
associated with systemic subclinical inflammation? Gynecol Obstet Invest. 
2006;62:139-47.
21. Cho S, Cho H, Nam A, Kim HY, Choi YS, Park KH, et al. Neutrophil-to-
lymphocyte ratio as an adjunct to CA-125 for the diagnosis of endometriosis. 
Fertil Steril 2008;90:2073-9.
22. Abrão MS, Gonçalves MOC, Dias Jr JA, Podgaec S, Chamie LP, Blasbalg R. 
Comparison between clinical examination, transvaginal sonography and 
magnetic resonance imaging for the diagnosis of deep endometriosis. Hum 
Reprod. 2007;22:3092-7.
23. Mikhaleva LM, Vorobeva NN, Samsonova MV. Ovarian endometriosis: 
characteristics of the blood circulatory bed. Arkh Patol. 2006;68:20-2.
